colistin has become a critical antibiotic for fatal Gram-negative infections owing to the proliferation of multidrug-resistant carbapenemase-producing bacteria. Thus, cheaper, faster, efficient and easier-touse colistin diagnostics are required for clinical surveillance, diagnoses and therapeutics. the sensitivity, specificity, major error (ME), very major error (VME), categorial agreement, essential agreement, turnaround time (TAT), average cost, and required skill for four colistin resistance diagnostics viz., cHRoMagar coL-APSE, ComASP Colistin, MicroScan, and Colistin MAC Test (CMT) were evaluated against broth microdilution (BMD) using 84 Gram-negative bacterial isolates. A multiplex PCR (M-PCR) was used to screen all isolates to detect the presence of the mcr-1 to mcr-5 genes. A 15-point grading scale was used to grade the tests under skill, ease, processing time etc. mcr-1 was detected by both M-pcR and cMt in a single E. coli isolate, with other pcR amplicons suggestive of mcr-2,-3 and-4 genes being also observed on the gel. The sensitivity and specificity of CHROMagar COL-APSE, MicroScan, and ComASP Colistin, were 82.05% and 66.67%, 92.31% and 76.92%, and 100% and 88.89% respectively. The MicroScan was the most expensive at a cost (per sampe tested) of R221.6 ($15.0), followed by cHRoMagar coL-APSE (R118.3; $8.0), M-PCR (R75.1; $5.1), CMT (R20.1; $1.4) and ComASP Colistin (R2.64; $0.2). CHROMagar was the easiest to perform, followed by ComASP Colistin, M-PCR, MicroScan, cMt and BMD whilst M-pcR and MicroScan required higher skill. the comASp colistin was the best performing diagnostic test, with low VME and ME, making it recommendable for routine colistin sensitivity testing in clinical laboratories; particularly, in poorer settings. It is however limited by a TAT of 18-24 hours. Subsequent to the exponential dissemination of extended-spectrum β-lactamases (ESBLs) in Gram-negative bacteria (GNB) and the increased use of carbapenems to treat infections unresponsive to the penicillins and cephems (cephalosporins and cephamycins), carbapenemase-producing and carbapenem-resistant GNB are becoming common worlwide 1,2. Thus, carbapenems, which are last-resort antibiotics, are being replaced by colistin, a polymyxin that was discovered many years ago but shelved over nephrotoxicity and neurotoxicity concerns 2,3. Resistance to colistin, due to its increased use to treat carbapenem-resistant GNB, has also emerged 2-4. Beginning from 2016, colistin resistance, which hitherto was mediated my chromosomal mutations, was found to be also mediated by plasmid-borne mcr genes 5,6. The high fatalities caused by colistin and/or carbapenem-resistant GNB infections have led to their being categorised as high-priority pathogens by the WHO 7,8. The clinical importance of colistin-resistant GNB (CR-GNB) necessitates an efficient diagnostic protocol for quickly and efficiently detecting them to preempt further escalation and mortalities 9 .